HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutritionals' Absence From Dietary Guidelines Baffles Industry, Researchers

This article was originally published in The Tan Sheet

Executive Summary

A draft of the 2010 U.S. dietary guidelines marks a step backward for promoting dietary supplements as components of healthy diets, but also should push the industry to step up for the next guideline, stakeholders say

You may also be interested in...

More Multivitamin Research Needed To Show Disease Prevention – NIH Panel

Members of an independent NIH panel evaluating the safety and effectiveness of multivitamin/minerals (MVMs) hope that a draft report containing their recommendations will spur action on research efforts for the supplement category

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts